Study drugs for Richter transformation in CLL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests zanubrutinib plus tislelizumab, with or without sonrotoclax, for people whose CLL has changed into Richter transformation (an aggressive lymphoma). It aims to improve anti-cancer response while tracking side effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed CLL, and your diagnosis matches accepted criteria for CLL.
- You have confirmed Richter transformation (a specific type of lymphoma on tissue biopsy).
- Your Richter transformation is either not yet treated, or you had a response that was not enough, or you couldn’t tolerate first treatment for it.
- Your blood counts and organ function are strong enough for treatment (often measured by neutrophils, platelets, kidneys, and liver tests).
- Your infection tests are negative or controlled (no active hepatitis B/C, and no active HIV; testing must be recent).
- You can take oral medicines as directed, and you’re well enough to attend study visits (age 18+, generally ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two newer drugs can help people with certain types of B-cell lymphoma that have come back or not responded to treatment. The drugs target cancer cells differently than older treatments, possibly offering a new option.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
Hear when a new Richter Transformation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.